Latest News in the pharma Industry

Research & Development

Ashland presents science-based strategy to enhance pharmaceutical formulation quality and advance drug delivery

Ashland presents science-based strategy to enhance pharmaceutical formulation quality and advance drug delivery

29 Oct 2015

A scientific approach to select polymer excipients that will better serve the pharmaceutical industry.

Read more 
Shire's OPUS-3 Phase II trial with lifitegrast meets primary and key secondary endpoints, significantly reducing patient-reported symptoms for dry eye disease

Shire's OPUS-3 Phase II trial with lifitegrast meets primary and key secondary endpoints, significantly reducing patient-reported symptoms for dry eye disease

29 Oct 2015

Data to support lifitegrast FDA resubmission in Q1 2016; plans on track for potential 2016 launch.

Read more 
Affinivax to collaboration with ClearPath and Astellas to develop vaccines to prevent nosocomial infections

Affinivax to collaboration with ClearPath and Astellas to develop vaccines to prevent nosocomial infections

28 Oct 2015

Collaboration will utilize Affinivax’s novel MAPS Vaccine Technology Platform.

Read more 
Agilent Technologies introduces industry’s most sensitive GC/MSD system

Agilent Technologies introduces industry’s most sensitive GC/MSD system

27 Oct 2015

Pollutants and contaminants can now be detected at previously undetectable levels.

Read more 
BioGenes launches enhanced generic E.coli host cell protein assay for biomanufacturing

BioGenes launches enhanced generic E.coli host cell protein assay for biomanufacturing

27 Oct 2015

The E.coli|360-HCP ELISA allows sponsors and biotech companies to postpone the development of a cost-intensive specific HCP assay until a more informed decision on the success of a biologic in development can be made.

Read more 
Amgen receives CHMP positive opinion for Imlygic

Amgen receives CHMP positive opinion for Imlygic

25 Oct 2015

If approved by the European Commission, Imlygic would be the first in a class of novel agents known as oncolytic immunotherapies.

Read more 
Lilly and AstraZeneca expand immuno-oncology research collaboration with new combinations

Lilly and AstraZeneca expand immuno-oncology research collaboration with new combinations

23 Oct 2015

AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), will be combined with Lilly molecules that target the immune system.

Read more 
Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx to treat ankylosing spondylitis and psoriatic arthritis

Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx to treat ankylosing spondylitis and psoriatic arthritis

23 Oct 2015

Cosentyx demonstrated rapid onset of action and long-term sustainability in patients with and without prior treatment using anti-tumour-necrosis-factor (anti-TNF) therapy.

Read more 
Metrion Biosciences becomes independent CRO

Metrion Biosciences becomes independent CRO

22 Oct 2015

Management team completes buy out of specialist ion channel research business from Xention.

Read more 
Impax receives FDA approval for generic version of Intuniv (guanfacine)

Impax receives FDA approval for generic version of Intuniv (guanfacine)

22 Oct 2015

Third generic product approved since the resolution of the warning letter at the Hayward facility.

Read more 
Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics

21 Oct 2015

With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the body's immune system to combat cancers.

Read more 
Synta announces termination for futility of ganetespib Phase III GALAXY-2 trial in lung cancer

Synta announces termination for futility of ganetespib Phase III GALAXY-2 trial in lung cancer

21 Oct 2015

IDMC concludes that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel alone.

Read more